Design, synthesis, structure, in vitro cytotoxic activity evaluation and docking studies on target enzyme GSK-3β of new indirubin-3ʹ-oxime derivatives

[1]  Trung Hai Nguyen,et al.  Oversampling Free Energy Perturbation Simulation in Determination of the Ligand‐Binding Free Energy , 2019, J. Comput. Chem..

[2]  Son Tung Ngo,et al.  Effective Estimation of Ligand-Binding Affinity Using Biased Sampling Method , 2019, ACS omega.

[3]  Claudio N. Cavasotto,et al.  Computational chemistry in drug lead discovery and design , 2018, International Journal of Quantum Chemistry.

[4]  M. Bouachrine,et al.  Investigation of indirubin derivatives: a combination of 3D-QSAR, molecular docking, and ADMET towards the design of new DRAK2 inhibitors , 2018, Structural Chemistry.

[5]  Son Tung Ngo,et al.  Determination of the absolute binding free energies of HIV-1 protease inhibitors using non-equilibrium molecular dynamics simulations , 2017 .

[6]  Liliana M. Pacureanu,et al.  Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors , 2017, Molecular Diversity.

[7]  Minh Tho Nguyen,et al.  Fast and accurate determination of the relative binding affinities of small compounds to HIV‐1 protease using non‐equilibrium work , 2016, J. Comput. Chem..

[8]  N. Cuc,et al.  Semi-synthesis of indirubin-3′-oxime from Strobilanthes cusia leaves, its acute and sub-chronic toxicity, in vitro and in vivo antitumor activity in Lewis lung carcinoma bearing mice , 2016 .

[9]  J. Gairin,et al.  Cytotoxic, apoptotic, and sensitization properties of ent‐kaurane‐type diterpenoids from Croton tonkinensis Gagnep on human liver cancer HepG2 and Hep3b cell lines , 2016, Fundamental & clinical pharmacology.

[10]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[11]  J. Sack.  CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032) , 2015 .

[12]  T. Uchiyama,et al.  Indirubin 3'-(O-oxiran-2-ylmethyl)oxime: a novel anticancer agent. , 2015, Bioorganic & medicinal chemistry letters.

[13]  Beata Szefler,et al.  Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2 , 2015, Journal of Molecular Modeling.

[14]  Holger Gohlke,et al.  Binding Free Energy Calculations for Lead Optimization: Assessment of Their Accuracy in an Industrial Drug Design Context. , 2014, Journal of chemical theory and computation.

[15]  S. Lenzen,et al.  Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors , 2014, BMC Research Notes.

[16]  Julio Caballero,et al.  Docking and quantitative structure–activity relationship of oxadiazole derivates as inhibitors of GSK3$$\upbeta $$β , 2014, Molecular Diversity.

[17]  David J. Duffy,et al.  GSK3 Inhibitors Regulate MYCN mRNA Levels and Reduce Neuroblastoma Cell Viability through Multiple Mechanisms, Including p53 and Wnt Signaling , 2013, Molecular Cancer Therapeutics.

[18]  F. Gago,et al.  A structure-based design of new C2- and C13-substituted taxanes: tubulin binding affinities and extended quantitative structure-activity relationships using comparative binding energy (COMBINE) analysis. , 2013, Organic & biomolecular chemistry.

[19]  A. Skaltsounis,et al.  From Tyrian Purple to Kinase Modulators: Naturally Halogenated Indirubins and Synthetic Analogues , 2012, Planta Medica.

[20]  H. Pradeep,et al.  A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3β , 2012, Molecular Diversity.

[21]  J. Veuthey,et al.  Analysis of anticancer drugs: a review. , 2011, Talanta.

[22]  F. Monsma,et al.  Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs , 2010, Expert opinion on drug discovery.

[23]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[24]  S Vadivelan,et al.  Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. , 2009, European journal of medicinal chemistry.

[25]  Michael P. Mazanetz,et al.  Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases , 2007, Nature Reviews Drug Discovery.

[26]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[27]  Jaroslav Koca,et al.  CAVER: a new tool to explore routes from protein clefts, pockets and cavities , 2006, BMC Bioinformatics.

[28]  A. Ougolkov,et al.  Targeting GSK-3: a promising approach for cancer therapy? , 2006, Future oncology.

[29]  J. C. Ghosh,et al.  Activation of p53-Dependent Apoptosis by Acute Ablation of Glycogen Synthase Kinase-3β in Colorectal Cancer Cells , 2005, Clinical Cancer Research.

[30]  S. Knapp,et al.  Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. , 2003, Journal of molecular biology.

[31]  Kirk W. Johnson,et al.  Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. , 2002, Diabetes.

[32]  A. Olson,et al.  Modelling of Factor Xa‐inhibitor complexes: a computational flexible docking approach , 1999, Proteins.

[33]  Sung-Hou Kim,et al.  Crystal structure of cyclin-dependent kinase 2 , 1993, Nature.

[34]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[35]  D. Scudiero,et al.  Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. , 1991, Journal of the National Cancer Institute.

[36]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[37]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. , 1981, Methods in enzymology.

[38]  R. C. Macridis.  A review , 1963 .

[39]  H. Pandraud.  Structure cristalline de l'indirubine , 1961 .

[40]  Liliana M. Pacureanu,et al.  QSAR study and molecular docking on indirubin inhibitors of Glycogen Synthase Kinase-3 , 2012 .

[41]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[42]  I. Xenarios,et al.  Molecular docking of competitive phosphodiesterase inhibitors. , 2002, Molecular pharmacology.

[43]  P. Cohen,et al.  Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. , 1980, European journal of biochemistry.